ATE160143T1 - 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten - Google Patents

2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten

Info

Publication number
ATE160143T1
ATE160143T1 AT94911608T AT94911608T ATE160143T1 AT E160143 T1 ATE160143 T1 AT E160143T1 AT 94911608 T AT94911608 T AT 94911608T AT 94911608 T AT94911608 T AT 94911608T AT E160143 T1 ATE160143 T1 AT E160143T1
Authority
AT
Austria
Prior art keywords
pct
formula
gaba
antagonists
sec
Prior art date
Application number
AT94911608T
Other languages
German (de)
English (en)
Inventor
Shen-Chun Kuo
David J Blythin
William Kreutner
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE160143T1 publication Critical patent/ATE160143T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/121,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • C07F9/65335Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94911608T 1993-03-26 1994-03-23 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten ATE160143T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3858493A 1993-03-26 1993-03-26

Publications (1)

Publication Number Publication Date
ATE160143T1 true ATE160143T1 (de) 1997-11-15

Family

ID=21900746

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94911608T ATE160143T1 (de) 1993-03-26 1994-03-23 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten

Country Status (14)

Country Link
US (1) US5929236A (en, 2012)
EP (1) EP0690850B1 (en, 2012)
JP (1) JP2778832B2 (en, 2012)
AT (1) ATE160143T1 (en, 2012)
AU (1) AU6408894A (en, 2012)
CA (1) CA2158952C (en, 2012)
DE (1) DE69406779T2 (en, 2012)
DK (1) DK0690850T3 (en, 2012)
ES (1) ES2109683T3 (en, 2012)
GR (1) GR3025950T3 (en, 2012)
IL (1) IL109111A (en, 2012)
TW (1) TW280817B (en, 2012)
WO (1) WO1994022843A1 (en, 2012)
ZA (1) ZA942090B (en, 2012)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853626A1 (en) * 1995-09-07 1998-07-22 Novartis AG Substituted phosphinic compounds and their use as pharmaceuticals
AU5859598A (en) * 1996-12-24 1998-07-17 Novartis Ag (thio)morpholine-substituted carboxylic and phosphinic acids
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889857A (en) * 1987-10-12 1989-12-26 Yoshitomi Pharmaceutical Industries, Ltd. Quinolonecarboxylic acid compounds and pharmaceutical use thereof
NZ233503A (en) * 1989-05-15 1991-06-25 Janssen Pharmaceutica Nv Substituted (thio)morpholinyl and piperazinyl alkylphenol ethers
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法

Also Published As

Publication number Publication date
TW280817B (en, 2012) 1996-07-11
AU6408894A (en) 1994-10-24
DE69406779D1 (en) 1997-12-18
ES2109683T3 (es) 1998-01-16
GR3025950T3 (en) 1998-04-30
EP0690850A1 (en) 1996-01-10
IL109111A0 (en) 1994-06-24
CA2158952A1 (en) 1994-10-13
ZA942090B (en) 1994-09-26
CA2158952C (en) 1999-05-18
WO1994022843A1 (en) 1994-10-13
JPH08503229A (ja) 1996-04-09
JP2778832B2 (ja) 1998-07-23
IL109111A (en) 1999-07-14
US5929236A (en) 1999-07-27
DK0690850T3 (da) 1998-02-09
EP0690850B1 (en) 1997-11-12
DE69406779T2 (de) 1998-03-12

Similar Documents

Publication Publication Date Title
KR960703598A (ko) 신경 질환 치료제(agent for curing neurotic diseases)
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
PT1158973E (pt) Utilizacao de derivados de sulfamato para o tratamento dos disturbios do controlo de impulsos
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
HUP0001062A2 (hu) NAALADáz gátló hatású foszfinsavszármazékokat tartalmazó gyógyászati készítmények
ATE160143T1 (de) 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
RU94044454A (ru) Ингибитор аутоимунных заболеваний
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
ATE174508T1 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
PT838223E (pt) Inibidor do edema cerebral
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
KR950031085A (ko) 표피증식 질환 치료용 의약 조성물
KR950701623A (ko) 치환된 헥사하이드로벤조페난트리딘
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
DE69421694D1 (en) Interleukin-1 inhibitor
KR960003719A (ko) 녹내장 치료제 및 안압 강하제
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
DE69421457D1 (de) Verwendung von N-(Pyridinyl)-1H-Indol-1-Aminen zur Herstellung eines Medikamentes zur Behandlung von zwangsneurotischen Erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee